Roth Capital analyst Yasmeen Rahimi raised the firm's price target on Moderna to $33 from $24 and keeps a Buy rating on the shares. The analyst notes that with its Q4 update, the company continued to emphasize the de-risked nature of mRNA prophylactic vaccines and its strategic focus at making CMV the backbone of Moderna's future.
IBM (IBM) is scheduled to report results of its fiscal first quarter after the market close on April 19, with a conference call scheduled for 5:00 pm ET. What to watch... To see the rest of the story go to thefly.com. See Story Here